Table 7 Results of cost-effectiveness analyses, Bacterial meningitis model
From: Risk-stratification in febrile infants 29 to 60 days old: a cost-effectiveness analysis
Cost ($) | Incremental Cost ($) | Effectiveness (QALY) | Incremental Effectiveness (QALY) | ICER ($/QALY) | |
|---|---|---|---|---|---|
PECARN | $4290 | 0.689 | |||
Boston | $4398 | $108 | 0.779 | 0.090 | $1198 |
Step-by-Step | $4669 | $272 | 0.773 | −0.006 | Dominated |
Aronson | $5015 | $617 | 0.772 | −0.007 | Dominated |
Rochester | $5308 | $911 | 0.772 | −0.007 | Dominated |
Philadelphia | $5466 | $1068 | 0.771 | −0.008 | Dominated |
Clinical suspicion | $5518 | $1120 | 0.734 | −0.046 | Dominated |
Modified Philadelphia | $5824 | $1426 | 0.771 | −0.008 | Dominated |